{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:21:56Z","timestamp":1791364916728,"version":"4.3.1"},"reference-count":237,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02847","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:58:39Z","timestamp":1575334719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":286,"title":["Emerging Topical and Systemic JAK Inhibitors in Dermatology"],"prefix":"10.3389","volume":"10","author":[{"given":"Farzan","family":"Solimani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00281-015-0545-x","article-title":"Cutaneous immunology: basics and new concepts","volume":"38","author":"Yazdi","year":"2016","journal-title":"Semin Immunopathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.12688\/f1000research.7927.1","article-title":"Recent advances in understanding psoriasis","volume":"5","author":"Eberle","year":"2016","journal-title":"F1000Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","article-title":"TH1\/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus","volume":"142","author":"Schmidt","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","article-title":"Therapeutic targeting of Th17\/Tc17 cells leads to clinical improvement of lichen planus","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/exd.13548","article-title":"A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis","volume":"27","author":"Bruck","year":"2018","journal-title":"Exp Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"B16","first-page":"1511","article-title":"Relationship of structure to function of muscle phosphorylase","volume":"25","author":"Fischer","year":"1966","journal-title":"Fed Proc"},{"key":"B17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be?","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.0105-2896.2005.00220.x","article-title":"Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs","volume":"203","author":"Pesu","year":"2005","journal-title":"Immunol Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1021\/acs.jmedchem.8b00571","article-title":"Development, optimization, and structure-activity relationships of covalent-reversible JAK3 inhibitors based on a tricyclic imidazo[5,4- d]pyrrolo[2,3- b]pyridine scaffold","volume":"61","author":"Forster","year":"2018","journal-title":"J Med Chem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2174\/1389557519666190617152011","article-title":"Current status in the discovery of covalent Janus kinase 3 (JAK3) inhibitors","volume":"19","author":"Dai","year":"2019","journal-title":"Mini Rev Med Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","article-title":"Topical Janus kinase inhibitors: a review of applications in dermatology","volume":"79","author":"Hosking","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2009.04.031","article-title":"National Alopecia Areata R. History of atopy or autoimmunity increases risk of alopecia areata","volume":"61","author":"Barahmani","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaad.2010.08.032","article-title":"Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study","volume":"65","author":"Chu","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","article-title":"Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history","volume":"20","author":"Goh","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A road map for those who don't know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jid.2017.09.046","article-title":"Genome-wide microRNA analysis implicates miR-30b\/d in the etiology of alopecia areata","volume":"138","author":"Tafazzoli","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/jdv.15383","article-title":"Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata","volume":"33","author":"Gordon","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jdcr.2019.02.007","article-title":"Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata","volume":"5","author":"Rachubinski","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jdcr.2018.07.018","article-title":"Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes","volume":"4","author":"Craiglow","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(18)32987-8","article-title":"JAK inhibitors and alopecia areata","volume":"393","author":"Gilhar","year":"2019","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jaci.2015.06.047","article-title":"Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum","volume":"136","author":"Gao","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","article-title":"Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march","volume":"139","author":"Czarnowicki","year":"2017","journal-title":"J Allergy Clin Immun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/labinvest.3700663","article-title":"IL-33 can promote survival, adhesion and cytokine production in human mast cells","volume":"87","author":"Iikura","year":"2007","journal-title":"Lab Invest"},{"key":"B55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.molimm.2014.06.018","article-title":"The role of the IL-33\/IL-1RL1 axis in mast cell and basophil activation in allergic disorders","volume":"63","author":"Saluja","year":"2015","journal-title":"Mol Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.713.","article-title":"Increased interleukin-26 expression promotes Th17 and Th2-associated cytokine production by keratinocytes in atopic dermatitis","author":"Kamijo","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1006659","DOI":"10.1371\/journal.pgen.1006659","article-title":"A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma","volume":"13","author":"Smith","year":"2017","journal-title":"PLoS Genet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jdcr.2017.12.016","article-title":"Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor","volume":"4","author":"Morris","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/08998280.2018.1480246","article-title":"Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib","volume":"31","author":"Haugh","year":"2018","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1346-8138.14322","article-title":"Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis","volume":"45","author":"Nakagawa","year":"2018","journal-title":"J Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/bjd.15607","article-title":"The pathogenesis of dermatomyositis","volume":"179","author":"Thompson","year":"2018","journal-title":"Br J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B75","first-page":"77","article-title":"Dermatomyositis and malignancy: a retrospective study of 115 cases","volume":"13","author":"Zhang","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","article-title":"Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment","volume":"77","author":"Hornig","year":"2018","journal-title":"Z Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/archderm.134.5.602","article-title":"Cutaneous graft-versus-host disease","volume":"134","author":"Aractingi","year":"1998","journal-title":"Arch Dermatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"515.e1","DOI":"10.1016\/j.jaad.2011.11.960","article-title":"Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease","volume":"66","author":"Hymes","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood-2013-07-514372","article-title":"Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease","volume":"123","author":"Bruggen","year":"2014","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1684\/ejd.2008.0517","article-title":"PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease","volume":"18","author":"Ghoreschi","year":"2008","journal-title":"Eur J Dermatol"},{"key":"B90","first-page":"745","article-title":"Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease","volume":"13","author":"Imamura","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa022060","article-title":"Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation","volume":"349","author":"Lin","year":"2003","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1182\/blood.V98.5.1594","article-title":"Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation","volume":"98","author":"Cavet","year":"2001","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","article-title":"IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD","volume":"120","author":"Choi","year":"2012","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/jid.2013.476","article-title":"Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib","volume":"134","author":"Okiyama","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1186\/s12885-018-5045-7","article-title":"Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)","volume":"18","author":"von Bubnoff","year":"2018","journal-title":"BMC Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1126\/science.1196284","article-title":"Gamma-secretase gene mutations in familial acne inversa","volume":"330","author":"Wang","year":"2010","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Mendonca","year":"2006","journal-title":"Br J Dermatol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.det.2015.08.013","article-title":"Antibiotic treatment of hidradenitis suppurativa","volume":"34","author":"Bettoli","year":"2016","journal-title":"Dermatol Clin"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2340\/00015555-3012","article-title":"Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: post hoc analysis of pooled data from PIONEER I and II","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Clinical practice. Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1600-0560.2006.00527.x","article-title":"Type I interferon-associated cytotoxic inflammation in lichen planus","volume":"33","author":"Wenzel","year":"2006","journal-title":"J Cutan Pathol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"eaav7561","DOI":"10.1126\/scitranslmed.aav7561","article-title":"IFN-\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus","volume":"11","author":"Shao","year":"2019","journal-title":"Sci Transl Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"801974","DOI":"10.1155\/2013\/801974","article-title":"Immunoexpression of interleukin-22 and interleukin-23 in oral and cutaneous lichen planus lesions: a preliminary study","volume":"2013","author":"Chen","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B111","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/odi.12094","article-title":"Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus","volume":"20","author":"Piccinni","year":"2014","journal-title":"Oral Dis"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/j.1365-2133.2011.10793.x","article-title":"Possible role of interleukin-17 in the pathogenesis of lichen planus","volume":"166","author":"Shaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e12656","DOI":"10.1111\/dth.12656","article-title":"Tofacitinib for the treatment of lichen planopilaris: a case series","volume":"31","author":"Yang","year":"2018","journal-title":"Dermatol Ther"},{"key":"B114","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"B116","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/eji.201445144","article-title":"Ultraviolet light converts propranolol, a nonselective beta-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand","volume":"45","author":"Dorgham","year":"2015","journal-title":"Eur J Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2010.176","article-title":"Genetic susceptibility to systemic lupus erythematosus in the genomic era","volume":"6","author":"Deng","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aar7201","article-title":"Translocation of a gut pathobiont drives autoimmunity in mice and humans","volume":"359","author":"Manfredo Vieira","year":"2018","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00281-015-0550-0","article-title":"Lupus erythematosus revisited","volume":"38","author":"Kuhn","year":"2016","journal-title":"Semin Immunopathol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"E898","DOI":"10.3390\/cells8080898","article-title":"Pathogenic and therapeutic relevance of JAK\/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent","volume":"8","author":"Alunno","year":"2019","journal-title":"Cells"},{"key":"B121","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/0961203306075383","article-title":"Activation of the STAT1 signalling pathway in lupus nephritis in MRL\/lpr mice","volume":"16","author":"Dong","year":"2007","journal-title":"Lupus"},{"key":"B122","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1089\/jir.2004.24.717","article-title":"An essential role for IFN-alpha in the overexpression of Fas ligand on MRL\/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential","volume":"24","author":"Hadj-Slimane","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/art.39535","article-title":"Development of Th17-associated interstitial kidney inflammation in lupus-prone mice lacking the gene encoding STAT-1","volume":"68","author":"Yiu","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/art.24449","article-title":"Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells","volume":"60","author":"Karonitsch","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B125","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-2249.2012.04676.x","article-title":"Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis","volume":"171","author":"Lu","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"key":"B127","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.4049\/jimmunol.1502043","article-title":"STAT3 signaling in B cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus","volume":"196","author":"Ding","year":"2016","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.clim.2006.03.009","article-title":"STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus","volume":"120","author":"Xu","year":"2006","journal-title":"Clin Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.4049\/jimmunol.1101228","article-title":"Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2","volume":"187","author":"Lu","year":"2011","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"B131","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2019.1608821","article-title":"Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update","volume":"15","author":"Kubo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"B133","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS ONE"},{"key":"B135","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.1003244","article-title":"Involvement of tyrosine kinase-2 in both the IL-12\/Th1 and IL-23\/Th17 axes in vivo","volume":"187","author":"Ishizaki","year":"2011","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B139","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br J Dermatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat."},{"key":"B146","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"e12467","DOI":"10.1111\/dth.12467","article-title":"Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis","volume":"30","author":"Bagherani","year":"2017","journal-title":"Dermatol Ther"},{"key":"B151","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMcp0804388","article-title":"Clinical practice. Vitiligo","volume":"360","author":"Taieb","year":"2009","journal-title":"N Engl J Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines","volume":"51","author":"Grimes","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Wankowicz-Kalinska","year":"2003","journal-title":"Lab Invest"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The use of Janus kinase inhibitors in vitiligo: a review of the literature","volume":"23","author":"Relke","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18606","article-title":"Open label pilot study of 2% tofacitinib for the treatment of refractory vitiligo","author":"Mobasher","year":"2019","journal-title":"Br J Dermatol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40257-012-0006-4","article-title":"Diagnosis and treatment of lichen sclerosus an update","volume":"14","author":"Fistarol","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/jid.2011.369","article-title":"An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155","volume":"132","author":"Terlou","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/bjd.13493","article-title":"The genetics of pyoderma gangrenosum and implications for treatment: a systematic review","volume":"172","author":"DeFilippis","year":"2015","journal-title":"Br J Dermatol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjd.16468","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu","year":"2018","journal-title":"Br J Dermatol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ibd.20023","article-title":"Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment","volume":"13","author":"Freysdottir","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"B173","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/archderm.139.2.136","article-title":"Successful treatment of granulomatous cheilitis with thalidomide","volume":"139","author":"Thomas","year":"2003","journal-title":"Arch Dermatol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1111\/jdv.15654","article-title":"Successful treatment of cheilitis granulomatosa with lenalidomide","volume":"33","author":"Solimani","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","article-title":"The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures","volume":"99","author":"McHugh","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ecco-jcc\/jjx158","article-title":"Expression patterns of TNF\u03b1, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease","volume":"12","author":"Vavricka","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B177","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"B178","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","author":"Damsky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B181","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2019.00281","article-title":"Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary sjogren's syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/3-211-27377-8_13","article-title":"Sjogren's syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/eji.201747213","article-title":"Aberrant cell signalling in PBMCs upon IFN-\u03b1 stimulation in primary Sjogren's syndrome patients associates with type I interferon signature","volume":"48","author":"Davies","year":"2018","journal-title":"Eur J Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"B185","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B186","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4049\/jimmunol.1400063","article-title":"Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts","volume":"193","author":"Onda","year":"2014","journal-title":"J Immunol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.4049\/jimmunol.1203032","article-title":"Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation","volume":"190","author":"Choi","year":"2013","journal-title":"J Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/blood-2011-11-392985","article-title":"Functional STAT3 deficiency compromises the generation of human T follicular helper cells","volume":"119","author":"Ma","year":"2012","journal-title":"Blood"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double-blind, vehicle-controlled Phase 2a study","author":"Worm","year":"2019","journal-title":"Br J Dermatol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.jid.2017.05.025","article-title":"Nickel sulfate promotes IL-17A producing CD4+ T cells by an IL-23-dependent mechanism regulated by TLR4 and Jak-STAT pathways","volume":"137","author":"Bechara","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000347184","article-title":"Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis","volume":"91","author":"Fujii","year":"2013","journal-title":"Pharmacology"},{"key":"B196","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B197","doi-asserted-by":"publisher","first-page":"4246965","DOI":"10.1155\/2018\/4246965","article-title":"Gene expression profiling in behcet's disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy","volume":"2018","author":"Puccetti","year":"2018","journal-title":"J Immunol Res"},{"key":"B198","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Behcet's disease: a comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"J Autoimmun"},{"key":"B199","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"B200","doi-asserted-by":"publisher","first-page":"e11149","DOI":"10.1097\/MD.0000000000011149","article-title":"Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"B202","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the Oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"B203","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"B204","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/kew442","article-title":"Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis","volume":"56","author":"Tarp","year":"2017","journal-title":"Rheumatology"},{"key":"B205","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus kinase (JAK) Inhibitors for rheumatoid arthritis: how real is the risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.059.","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","author":"Sands","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00296-019-04303-x","article-title":"Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib","volume":"39","author":"Novikova","year":"2019","journal-title":"Rheumatol Int"},{"key":"B208","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/17474086.2017.1337507","article-title":"Managing side effects of JAK inhibitors for myelofibrosis in clinical practice","volume":"10","author":"Saeed","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/bph.13932","article-title":"Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis","volume":"174","author":"Perez-Baos","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jaci.2018.07.022","article-title":"Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations","volume":"143","author":"Hammaren","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000351940","article-title":"Drug delivery with topically applied nanoparticles: science fiction or reality","volume":"26","author":"Lademann","year":"2013","journal-title":"Skin Pharmacol Physiol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00105-018-4343-y","article-title":"Follicular penetration of nanocarriers is an important penetration pathway for topically applied drugs","volume":"70","author":"Lademann","year":"2019","journal-title":"Hautarzt"},{"key":"B213","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00105-004-0841-1","article-title":"Penetration of microparticles into human skin","volume":"55","author":"Lademann","year":"2004","journal-title":"Hautarzt"},{"key":"B214","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"B215","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"B216","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"B217","doi-asserted-by":"publisher","first-page":"E1548","DOI":"10.3390\/jcm8101548","article-title":"Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts","volume":"8","author":"Mueller","year":"2019","journal-title":"J Clin Med"},{"key":"B218","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/rheumatology\/kez175","article-title":"Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis","volume":"58","author":"Almanzar","year":"2019","journal-title":"Rheumatology"},{"key":"B223","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2018.03.002","article-title":"Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers","volume":"191","author":"Weinhold","year":"2018","journal-title":"Clin Immunol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1038\/s41598-017-07261-1","article-title":"A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"B227","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"B228","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B229","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B230","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"B231","doi-asserted-by":"publisher","first-page":"7492904","DOI":"10.1155\/2018\/7492904","article-title":"Are Janus kinase inhibitors superior over classic biologic agents in RA patients?","volume":"2018","author":"Kotyla","year":"2018","journal-title":"Biomed Res Int"},{"key":"B232","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1583711","article-title":"Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials","volume":"20","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B237","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02847\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:58:43Z","timestamp":1575334723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02847\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":237,"alternative-id":["10.3389\/fimmu.2019.02847"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02847","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737108259.793571800","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]},"article-number":"2847"}}